Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook (2018-2027)

  • ID: 4662328
  • Report
  • Region: Global
  • 75 Pages
  • Koncept Analytics
1 of 4
The Global NASH Drugs Market is Expected to Witness Lucrative Growth Due to the Mounting Occurrence of NASH, Rising Healthcare Expenditure, Increasing Obese Patient Population, Unmet Medical Needs and Sedentary Lifestyle

FEATURED COMPANIES

  • Allergan Plc (Tobira)
  • Genfit SA
  • Gilead Sciences, Inc.
  • MORE

Non-alcoholic Steatohepatitis or NASH is a common term for “silent” liver disease and can result into cirrhosis, in which liver is permanently damaged and after a certain point could lead to death. Currently, no specific medicines for NASH exist, but certain specialty drugs are expected to enter the market in the year 2020.

The global NASH drugs market is expected to witness lucrative growth due the mounting occurrence of NASH, rising healthcare expenditure, increasing obese patient population, unmet medical needs and sedentary lifestyle. The market is trending with rising pharmaceutical R&D expenditures, development of NASH diagnosis methods and biomarkers, progressing drugs under pipeline and intensifying e-commerce pharmaceutical products sales. However, there are some growth hindering factors in the market including lethargic drug approval process, high treatment cost and associated business risks.

Regionally, the U.S. is expected to hold the leading position in the market, due to constantly increasing prevalence of various types of liver disease and the local companies engaged in the manufacturing of NASH drugs.

The report “Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Industry Analysis & Outlook (2018-2027)” provides an extensive research and detailed analysis of the present market along with future outlook. Key players i.e. Gilead Sciences, Inc., Allergan Plc (Tobira), Intercept Pharmaceuticals, Inc., and Genfit SA are being profiled along with their respective financials and growth strategies.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan Plc (Tobira)
  • Genfit SA
  • Gilead Sciences, Inc.
  • MORE

1. Market Overview
1.1 Introduction
1.2 Causes & Symptoms
1.3 Diagnosis
1.4 Treatment

2. Global NASH Market
2.1 Global NASH Drugs Market Value Forecast
2.2 Global NASH Drugs Market Value Forecast by Drug Class
2.3 Global NASH Off-Label Drugs Market Value Forecast

3. Global NASH Therapeutics Market
3.1 Global NASH Therapeutics Market Value Forecast
3.2 Global NASH Therapeutics Market Value Forecast by Drug Type
3.2.1 Global Obeticholic Acid (OCA) Drug Value Forecast
3.2.2 Global Obeticholic Acid (OCA) Drug Value Forecast by Region
3.2.3 Global Cenicriviroc (CVC) Drug Value Forecast
3.2.4 Global Cenicriviroc (CVC) Drug Value Forecast by Region
3.2.5 Global Elafibranor Drug Value Forecast
3.2.6 Global Aramchol Drug Value Forecast
3.2.7 Global MGL-3196 Drug Value Forecast
3.2.8 Global INN-217 Drug Value Forecast
3.2.9 Global VK2809 Drug Value Forecast
3.3 Global NASH Therapeutics Market Value Forecast by Region

4. Regional NASH Market
4.1 The U.S. NASH Therapeutics Market Value Forecast
4.2 Europe NASH Therapeutics Market Value Forecast
4.3 RoW NASH Therapeutics Market Value Forecast

5. Market Dynamics
5.1 Growth Drivers
5.1.1 Mounting Occurrence of NASH
5.1.2 Rising HealthCare Expenditure
5.1.3 Swelling Obese Patient Population
5.1.4 Accelerating Economic Growth
5.1.5 Unmet Medical Needs
5.1.6 Sedentary Lifestyle
5.2 Key Trends & Development
5.2.1 Rising Pharmaceutical R&D Expenditures
5.2.2 Development of NASH Diagnosis Methods and Biomarkers
5.2.3 Progressing Drugs under Pipeline
5.2.4 Intensifying E-Commerce Pharmaceutical Products Sales
5.3 Challenges
5.3.1 Lethargic Drug Approval Process
5.3.2 High Treatment Cost
5.3.3 Associated Business Risk

6. Competitive Landscape
6.1 Global NASH Drugs Market
6.1.1 Key Players - Revenue Comparison
6.1.2 Key Players – Market Cap Comparison
6.1.3 Key Players – Product Portfolio Comparison

7. Company Profiles
7.1 Gilead Sciences, Inc.
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategies
7.2 Allergan Plc (Tobira)
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategies
7.3 Intercept Pharmaceuticals, Inc.
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategies
7.4 Genfit SA
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategies

List of Figures
NAFLD Spectrum and Estimated Advancement Risk
Potential Phase III NASH Drugs
Global NASH Drugs Market Value Forecast (2017-2027)
Global NASH Drugs Market Value Forecast by Drug Class (2017/2022/2027)
Global NASH Off-Label Drugs Market Value Forecast (2017-2027)
Global NASH Therapeutics Market Value Forecast (2020-2027)
Global NASH Therapeutics Market Value Forecast by Drug Type (2022)
Global NASH Therapeutics Market Value Forecast by Drug Type (2027)
Global Obeticholic Acid (OCA) Drug Value Forecast (2020-2027)
Global Obeticholic Acid (OCA) Drug Value Forecast by Region (2027)
Global Cenicriviroc (CVC) Drug Value Forecast (2020-2027)
Global Cenicriviroc (CVC) Drug Value Forecast by Region (2027)
Global Elafibranor Drug Value Forecast (2020-2027)
Global Aramchol Drug Value Forecast (2022-2027)
Global MGL-3196 Drug Value Forecast (2023-2027)
Global INN-217 Drug Value Forecast (2023-2027)
Global VK2809 Drug Value Forecast (2023-2027)
Global NASH Therapeutics Market Value Forecast by Region (2022)
Global NASH Therapeutics Market Value Forecast by Region (2027)
The U.S. NASH Therapeutics Market Value Forecast (2022-2027)
Europe NASH Therapeutics Market Value Forecast (2022-2027)
RoW NASH Therapeutics Market Value Forecast (2022-2027)
The U.S. NASH Patient Population (2017-2027)
Global HealthCare Expenditure Per Capita (2013-2017)
Global Obese Patient Population (2013-2017)
Global GDP Per Capita (2013-2017)
Global Pharmaceutical R&D Expenditures (2013-2017)
Global E-Commerce Pharmaceutical Products Sales (2017-2022)
Drugs Approval Process
Key Players - Market Cap Comparison (2018)
Gilead Sciences Revenues by Business Segments (2017)
Gilead Sciences Revenues and Net Income (2013-2017)
Gilead Sciences R&D Expenditure (2015-2017)
Allergan (Tobira) Net Revenues by Business Segments (2017)
Allergan (Tobira) Net Revenues and Net Loss (2013-2017)
Allergan (Tobira) R&D Expenditures (2015-2017)
Intercept Pharmaceuticals Revenue and Net Loss (2013-2017)
Intercept Pharmaceuticals A&P Expenditures (2015-2017)
Intercept Pharmaceuticals R&D Expenditures (2015-2017)
Genfit Revenues and Net Loss (2013-2017)
Genfit R&D Expenditures (2015-2017)

List of Tables
NASH Off-Label Therapies (2017)
Selected NASH Diagnosis Methods and Biomarkers under Development (2018)
Drugs under Development for NASH (2018)
NASH Annual Treatment Cost Comparison (2018)
Key Players - Revenue Comparison (2017)
Key Players – Product Portfolio Comparison (2018)
Intercept Pharmaceuticals Product Pipeline (2018)
Genfit Product Pipeline (2018)

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Allergan Plc (Tobira)
  • Genfit SA
  • Gilead Sciences, Inc.
  • Intercept Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll